| Molecular Formula | C18H19N3O3S.HCl |
| Molar Mass | 393.89 |
| Solubility | DMSO:79 mg/mL (200.56 mM);Ethanol:79 mg/mL (200.56 mM);Water :Insoluble |
| Appearance | White or white-like crystalline powder |
| Storage Condition | -20℃ |
| MDL | MFCD04112701 |
| overview | rosiglitazone is a hypoglycemic drug developed by SmithKline, and its product compound is disclosed in the European patent EP 306228. |
| use | rosiglitazone hydrochloride has better stability than rosiglitazone maleate, and is very suitable for application in the manufacture of common pharmaceutical preparations. This product is a thiazolidinedione antidiabetic drug, which can effectively control blood sugar by improving insulin sensitivity. |
| biological activity | Rosiglitazone HCl (BRL-49653) is a hypoglycemic drug that stimulates insulin secretion by binding to PPAR receptors in adipocytes. |
| Target | Value |